Pharmaceutical companies seeking nationwide growth in Nigeria have been advised not to rely solely on Lagos-based distribution networks, with industry experts warning that such strategies often limit product penetration across Northern Nigeria and other key commercial regions.
The warning comes amid growing discussions on pharmaceutical market access, as professionals argue that while Lagos remains Nigeria’s primary import and commercial hub, its distribution ecosystem alone cannot effectively support long-term expansion into states such as Kano, Kaduna, Jos, Maiduguri and Makurdi, where healthcare demand and trading patterns differ significantly.
According to industry insights shared by pharmaceutical market access specialist Bright Chimezie Irem, and reported by Brandspur Brand News, many international drug manufacturers establish their Nigerian operations around Lagos because of its seaports, concentration of distributors and relatively efficient logistics. However, companies frequently encounter slower growth once they attempt to expand beyond the South-West.
The analysis suggests that weaker sales performance outside Lagos is often linked to distribution strategy rather than limited demand. Regional supply chains across Northern Nigeria, the Middle Belt and secondary commercial centres operate differently, with distinct wholesaler relationships, inventory movement, purchasing behaviour and open-market dynamics influencing how pharmaceutical products reach healthcare providers and consumers.
Experts note that treating Nigeria as a single, uniform pharmaceutical market can create uneven product availability, leaving substantial parts of the country underserved despite growing healthcare needs. This imbalance may result in slower reorder cycles, inconsistent distributor engagement and reduced national market penetration over time.
Industry stakeholders argue that pharmaceutical companies achieving broader national success typically position Lagos as an entry point rather than the centre of their entire commercial strategy. They emphasise the importance of understanding regional distribution channels, monitoring purchasing trends across different markets and building stronger relationships with wholesalers and distributors beyond the country’s coastal commercial centres.
The discussion has also drawn support from other pharmaceutical professionals, who observed that medicine brands commonly available through Lagos distribution channels can differ from those more widely marketed across Kano and other northern states, highlighting the importance of region-specific market strategies.
As Nigeria’s healthcare and pharmaceutical sectors continue to expand, experts believe companies that adapt their distribution models to reflect regional commercial realities will be better positioned to achieve sustainable nationwide growth and improve access to medicines across the country.
